Structure-Driven Developments of 26S Proteasome Inhibitors

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 191-209

  ͆ledź, Paweł ^a,b   Baumeister, Wolfgang ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

19S regulatory particle; AAA ATPase; Deubiquitylation; Structure based drug design

Indexed keywords

19S PROTEASOME; 20S PROTEASOME; 26S PROTEASOME; 26S PROTEASOME INHIBITOR; ADENOSINE TRIPHOSPHATASE; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; MACROCYCLIC COMPOUND; NATURAL PRODUCT; PROTEASOME; PROTEASOME INHIBITOR; SYRBACTIN DERIVATIVE; UBIQUITIN; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE;

ARTICLE; BETA SHEET; COMPLEX FORMATION; COVALENT BOND; DRUG DESIGN; DRUG TARGETING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS;

EID: 84954168039     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124727     Document Type: Article

References (133)

1. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82(2):373-428
2. Finley D. 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78:477-513
3. Driscoll JJ, Dechowdhury R. 2010. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Target. Oncol. 5(4):281-89
4. Sterz J, von Metzler I, Hahne J-C, Lamottke B, Rademacher J, et al. 2008. The potential of proteasome inhibitors in cancer therapy. Expert Opin. Investig. Drugs 17(6):879-95
5. Orlowski RZ, Kuhn DJ. 2008. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14(6):1649-57
6. Nalepa G, Rolfe M, Harper JW. 2006. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5(7):596-613
7. Adams J. 2004. The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer 4(5):349-60
8. Adams J. 2002. Proteasome inhibition: A novel approach to cancer therapy. Trends Mol. Med. 8(4 Suppl.):S49-54
9. Fierabracci A. 2012. Proteasome inhibitors: A new perspective for treating autoimmune diseases. Curr. Drug Targets 13(13):1665-75
10. Wang J, Maldonado MA. 2006. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell. Mol. Immunol. 3(4):255-61
11. Adams J, Kauffman M. 2004. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investig. 22(2):304-11
12. Molineaux SM. 2012. Molecular pathways: targeting proteasomal protein degradation in cancer. Clin. Cancer Res. 18(1):15-20
13. Dahlmann B, Kopp F, Kuehn L,Niedel B, Pfeifer G, et al. 1989. Themulticatalytic proteinase (prosome) is ubiquitous from eukaryotes to archaebacteria. FEBS Lett. 251(1-2):125-31
14. Andricopulo AD, Salum LB, Abraham DJ. 2009. Structure-based drug design strategies in medicinal chemistry. Curr. Top. Med. Chem. 9(9):771-90
15. Whittle PJ, Blundell TL. 1994. Protein structure-based drug design. Annu. Rev. Biophys. Biomol. Struct. 23:349-75
16. Harrison C. 2012. Structure-based drug design: opening the door to an epigenetic target. Nat. Rev. Drug Discov. 11(9):672-73
17. Amzel LM. 1998. Structure-based drug design. Curr. Opin. Biotechnol. 9(4):366-69
18. Blundell TL. 1996. Structure-based drug design. Nature 384(6604 Suppl.):23-26
19. Murray CW, Rees DC. 2009. The rise of fragment-based drug discovery. Nat. Chem. 1(3):187-92
20. Mashalidis EH,Sledz P,Lang S, Abell C. 2013. A three-stage biophysical screening cascade for fragmentbased drug discovery. Nat. Protoc. 8(11):2309-24
21. Förster F, Unverdorben P,Sledz P, Baumeister W. 2013. Unveiling the long-held secrets of the 26S proteasome. Structure 21(9):1551-62
22. Wilk S, Orlowski M. 1980. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J. Neurochem. 35(5):1172-82
23. Orlowski M, Wilk S. 1981. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem. Biophys. Res. Commun. 101(3):814-22
24. Wilk S, Orlowski M. 1983. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. 40(3):842-49
25. Dahlmann B, Kuehn L, Rutschmann M, Reinauer H. 1985. Purification and characterization of a multicatalytic high-molecular-mass proteinase from rat skeletal muscle. Biochem. J. 228(1):161-70
26. Tanaka K, Ii K, Ichihara A, Waxman L, Goldberg AL. 1986. A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution. J. Biol. Chem. 261(32):15197-203
27. Hegerl R, Pfeifer G, Pühler G, Dahlmann B, BaumeisterW. 1991. The three-dimensional structure of proteasomes from Thermoplasma acidophilum as determined by electron microscopy using random conical tilting. FEBS Lett. 283(1):117-21
28. Zühl F,TamuraT,Dolenc I,Cejka Z, Nagy I, et al. 1997. Subunit topology of the Rhodococcus proteasome. FEBS Lett. 400(1):83-90
29. Seemüller E, Lupas A, Zühl F, Zwickl P, Baumeister W. 1995. The proteasome from Thermoplasma acidophilum is neither a cysteine nor a serine protease. FEBS Lett. 359(2-3):173-78
30. Seemüller E, Lupas A, Stock D, Löwe J,Huber R, BaumeisterW. 1995. Proteasome from Thermoplasma acidophilum: A threonine protease. Science 268(5210):579-82
31. Löwe J, Stock D, Jap B, Zwickl P, BaumeisterW,HuberR. 1995. Crystal structure of the 20S proteasome from the archaeon T. Acidophilum at 3. 4A resolution. Science 268(5210):533-39
32. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, et al. 1997. Structure of 20S proteasome from yeast at 2. 4A resolution. Nature 386(6624):463-71
33. Kniepert A, Groettrup M. 2014. The unique functions of tissue-specific proteasomes. Trends Biochem. Sci. 39(1):17-24
34. Baumeister W, Walz J, Zühl F, Seemüller E. 1998. The proteasome: paradigm of a selfcompartmentalizing protease. Cell 92(3):367-80
35. Kunjappu MJ,HochstrasserM. 2014. Assembly of the 20S proteasome. Biochim. Biophys. Acta 1843(1):2-12
36. Stadtmueller BM, Hill CP. 2011. Proteasome activators. Mol. Cell 41(1):8-19
37. Zhang F, Wu Z, Zhang P, Tian G, Finley D, Shi Y. 2009. Mechanism of substrate unfolding and translocation by the regulatory particle of the proteasome from Methanocaldococcus jannaschii. Mol. Cell 34(4):485-96
38. Forouzan D, Ammelburg M, Hobel CF, Ströh LJ, Sessler N, et al. 2012. The archaeal proteasome is regulated by a network of AAA ATPases. J. Biol. Chem. 287(46):39254-62
39. Barthelme D, Sauer RT. 2012. Identification of the Cdc4820S proteasome as an ancient AAA+ proteolytic machine. Science 337(6096):843-46
40. Rabl J, Smith DM, Yu Y, Chang S-C, Goldberg AL, Cheng Y. 2008. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol. Cell 30(3):360-68
41. Ruschak AM, Religa TL, Breuer S, Witt S, Kay LE. 2010. The proteasome antechamber maintains substrates in an unfolded state. Nature 467(7317):868-71
42. Lander GC, Estrin E,MatyskielaME, Bashore C, Nogales E,Martin A. 2012. Complete subunit architecture of the proteasome regulatory particle. Nature 482(7384):186-91
43. Lasker K, Forster F, Bohn S, Walzthoeni T, Villa E, et al. 2012. Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. PNAS 109(5):1380-87
44. Matyskiela ME, Lander GC, Martin A. 2013. Conformational switching of the 26S proteasome enables substrate degradation. Nat. Struct. Mol. Biol. 20(7):781-88
45. Sledz P, Unverdorben P, Beck F, Pfeifer G, Schweitzer A, et al. 2013. Structure of the 26S proteasome with ATP-S bound provides insights into the mechanism of nucleotide-dependent substrate translocation. PNAS 110(18):7264-69
46. Pathare GR, Nagy I, Bohn S, Unverdorben P, Hubert A, et al. 2012. The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. PNAS 109(1):149-54
47. Verma R, Aravind L, Oania R,McDonald WH, Yates JR, et al. 2002. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298(5593):611-15
48. Matyskiela ME, Martin A. 2013. Design principles of a universal protein degradation machine. J. Mol. Biol. 425(2):199-213
49. Sledz P, Förster F, Baumeister W. 2013. Allosteric effects in the regulation of 26S proteasome activities. J. Mol. Biol. 425(9):1415-23
50. Beck F, Unverdorben P, Bohn S, Schweitzer A, Pfeifer G, et al. 2012. Near-atomic resolution structural model of the yeast 26S proteasome. PNAS 109(37):14870-75
51. Vinitsky A, Cardozo C, Sepp-Lorenzino L,Michaud C, OrlowskiM. 1994. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J. Biol. Chem. 269(47):29860-66
52. McCormack TA, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, et al. 1998. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone. Biochemistry 37(21):7792-800
53. Vinitsky A, Michaud C, Powers JC, Orlowski M. 1992. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31(39):9421-28
54. Borissenko L, Groll M. 2007. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107(3):687-717
55. Kisselev AF, van der Linden WA, Overkleeft HS. 2012. Proteasome inhibitors: An expanding army attacking a unique target. Chem. Biol. 19(1):99-115
56. Braun HA, Umbreen S, GrollM, Kuckelkorn U,Mlynarczuk I, et al. 2005. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem. 280(31):28394-401
57. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. 1994. The ubiquitin-proteasome pathway is required for processing the NF-B1 precursor protein and the activation of NF-B. Cell 78(5):773-85
58. Lee DH, Goldberg AL. 1996. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem. 271(44):27280-84
59. Meng L, Mohan R, Kwok BH, ElofssonM, Sin N, Crews CM. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. PNAS 96(18):10403-8
60. GrollM, Berkers CR, PloeghHL, Ovaa H. 2006. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14(3):451-56
61. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, et al. 2008. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5):2765-75
62. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, et al. 2010. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5):1970-80
63. Gräwert MA, Gallastegui N, Stein M, Schmidt B, Kloetzel P-M, et al. 2011. Elucidation of the ketoaldehyde binding mechanism: A lead structure motif for proteasome inhibition. Angew. Chem. Int. Ed. Engl. 50(2):542-44
64. Screen M, Britton M, Downey SL, Verdoes M, Voges MJ, et al. 2010. Nature of pharmacophore influences active site specificity of proteasome inhibitors. J. Biol. Chem. 285(51):40125-34
65. Geurink PP, van der Linden WA, Mirabella AC, Gallastegui N, de Bruin G, et al. 2013. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J. Med. Chem. 56(3):1262-75
66. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, et al. 2008. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 452(7188):755-58
67. Clerc J, Groll M, Illich DJ, Bachmann AS, Huber R, et al. 2009. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. PNAS 106(16):6507-12
68. Coleman CS, Rocetes JP, Park DJ, Wallick CJ,Warn-Cramer BJ, et al. 2006. Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Cell Prolif. 39(6):599-609
69. Clerc J, Li N, Krahn D, Groll M, Bachmann AS, et al. 2011. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chem. Commun. 47(1):385-87
70. Stein ML, Beck P, Kaiser M, Dudler R, Becker CFW, Groll M. 2012. One-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitor. PNAS 109(45):18367-71
71. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, et al. 2000. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC1093. Taxonomy, production, isolation, and biological activities. J. Antibiot. 53(2):105-9
72. Groll M, Koguchi Y, Huber R, Kohno J. 2001. Crystal structure of the 20 S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J. Mol. Biol. 311(3):543-48
73. Kaiser M, Groll M, Renner C, Huber R, Moroder L. 2002. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem. Int. Ed. Engl. 41(5):780-83
74. Kaiser M, GrollM, Siciliano C, Assfalg-Machleidt I,Weyher E, et al. 2004. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. ChemBioChem 5(9):1256-66
75. Groll M, Götz M, Kaiser M, Weyher E, Moroder L. 2006. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 13(6):607-14
76. Basse N, Piguel S, Papapostolou D, Ferrier-Berthelot A, Richy N, et al. 2007. Linear TMC-95-based proteasome inhibitors. J. Med. Chem. 50(12):2842-50
77. Groll M, Gallastegui N, Maréchal X, Le Ravalec V, Basse N, et al. 2010. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A. ChemMedChem 5(10):1701-5
78. BrittonM, LucasMM,Downey SL, Screen M, Pletnev AA, et al. 2009. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem. Biol. 16(12):1278-89
79. Mirabella AC, Pletnev AA, Downey SL, Florea BI, Shabaneh TB, et al. 2011. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem. Biol. 18(5):608-18
80. Garca-Echeverra C, Imbach P, France D, Fürst P, Lang M, et al. 2001. A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome. Bioorg. Med. Chem. Lett. 11(10):1317-19
81. Furet P, Imbach P, Noorani M, Koeppler J, Laumen K, et al. 2004. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J. Med. Chem. 47(20):4810-13
82. Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, et al. 2010. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S5-subunit. Biochem. J. 430(3):461-76
83. BlackburnC, Barrett C, Blank JL, Bruzzese FJ, BumpN, et al. 2010. Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg. Med. Chem. Lett. 20(22):6581-86
84. Gaczynska M, Rock KL,Goldberg AL. 1993. Gamma-interferon and expression ofMHCgenes regulate peptide hydrolysis by proteasomes. Nature 365(6443):264-67
85. Driscoll J, Brown MG, Finley D, Monaco JJ. 1993. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365(6443):262-64
86. van Swieten PF, Samuel E, Hernández RO, van den Nieuwendijk AMCH, Leeuwenburgh MA, et al. 2007. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg. Med. Chem. Lett. 17(12):3402-5
87. Ho YK, Bargagna-Mohan P,WehenkelM,Mohan R, Kim K-B. 2007. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem. Biol. 14(4):419-30
88. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, et al. 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 15(7):781-87
89. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, et al. 2012. Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148(4):727-38
90. Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, et al. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25(13):5675-86
91. Kondo K, Kim WY, LechpammerM, KaelinWGJr. 2003. Inhibition of HIF2 is sufficient to suppress pVHL-defective tumor growth. PLOS Biol. 1(3):e83
92. Gordan JD, Bertout JA,HuC-J, Diehl JA, SimonMC. 2007. HIF-2 promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11(4):335-47
93. Li H, Ponder EL, VerdoesM, Asbjornsdottir KH, Deu E, et al. 2012. Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem. Biol. 19(12):1535-45
94. Hu G, Lin G,WangM, Dick L, Xu R-M, et al. 2006. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol. 59(5):1417-28
95. Lin G,Hu G, Tsu C, Kunes YZ, Li H, et al. 2006. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Mol. Microbiol. 59(5):1405-16
96. Lin G, Li D, de Carvalho LPS, DengH, Tao H, et al. 2009. Inhibitors selective for mycobacterial versus human proteasomes. Nature 461(7264):621-26
97. Lin G, Tsu C, Dick L, Zhou XK, Nathan C. 2008. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. J. Biol. Chem. 283(49):34423-31
98. Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, et al. 2013. N,C-capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets. J. Am. Chem. Soc. 135(27):9968-71
99. Gallastegui N, Beck P, Arciniega M, HuberR,Hillebrand S,Groll M. 2012. Hydroxyureas as noncovalent proteasome inhibitors. Angew. Chem. Int. Ed. Engl. 51(1):247-49
100. Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, et al. 2013. Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. PLOS ONE 8(4):e60649
101. Fenteany G, StandaertRF, Lane WS,Choi S,Corey EJ, Schreiber SL. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268(5211):726-31
102. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. 1996. Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasto-lactacystin lactone. J. Biol. Chem. 271(13):7273-76
103. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, et al. 1997. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272(1):182-88
104. GrollM, Huber R, Potts BCM. 2006. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 128(15):5136-41
105. Groll M, Balskus EP, Jacobsen EN. 2008. Structural analysis of spiro lactone proteasome inhibitors. J. Am. Chem. Soc. 130(45):14981-83
106. Groll M, McArthur KA, Macherla VR, Manam RR, Potts BC. 2009. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. J. Med. Chem. 52(17):5420-28
107. Asai A, Tsujita T, Sharma SV, Yamashita Y, Akinaga S, et al. 2004. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem. Pharmacol. 67(2):227-34
108. Groll M, Larionov OV, Huber R, de Meijere A. 2006. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. PNAS 103(12):4576-79
109. Kawamura S, Unno Y, List A, Mizuno A, Tanaka M, et al. 2013. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action. J. Med. Chem. 56(9):3689-700
110. Nyquist K, Martin A. 2014. Marching to the beat of the ring: polypeptide translocation by AAA+ proteases. Trends Biochem. Sci. 39(2):53-60
111. Sauer RT, Baker TA. 2011. AAA+ proteases: ATP-fueled machines of protein destruction. Annu. Rev. Biochem. 80:587-612
112. Hanson PI, Whiteheart SW. 2005. AAA+ proteins: have engine, will work. Nat. Rev. Mol. Cell Biol. 6(7):519-29
113. Neuwald AF, Aravind L, Spouge JL, Koonin EV. 1999. AAA+: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res. 9(1):27-43
114. Beckwith R, Estrin E, Worden EJ, Martin A. 2013. Reconstitution of the 26S proteasome reveals functional asymmetries in its AAA+ unfoldase. Nat. Struct. Mol. Biol. 20(10):1164-72
115. Lim H-S, Archer CT, Kodadek T. 2007. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle. J. Am. Chem. Soc. 129(25):7750-51
116. Lim H-S, Archer CT, Kim Y-C, Hutchens T, Kodadek T. 2008. Rapid identification of the pharmacophore in a peptoid inhibitor of the proteasome regulatory particle. Chem. Commun. 2008:1064-66
117. Chou T-F, Deshaies RJ. 2011. Development of p97 AAA ATPase inhibitors. Autophagy 7(9):1091-92
118. Chou T-F, Brown SJ, Minond D, Nordin BE, Li K, et al. 2011. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. PNAS 108(12):4834-39
119. Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, et al. 2013. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9:548-56
120. Firestone AJ, Weinger JS, MaldonadoM, Barlan K, Langston LD, et al. 2012. Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature 484(7392):125-29
121. Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172):1001-9
122. Coyne AG, Scott DE, Abell C. 2010. Drugging challenging targets using fragment-based approaches. Curr. Opin. Chem. Biol. 14(3):299-307
123. Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, et al. 2004. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306(5693):117-20
124. Bazzaro M, Anchoori RK, Mudiam MKR, Issaenko O, Kumar S, et al. 2011.,-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J. Med. Chem. 54(2):449-56
125. Anchoori RK, Karanam B, Peng S,Wang JW, Jiang R, et al. 2013. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 24(6):791-805
126. Peth A, Besche HC, Goldberg AL. 2009. Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol. Cell 36(5):794-804
127. Lee B-H, Lee MJ, Park S, Oh D-C, Elsasser S, et al. 2010. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467(7312):179-84
128. D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, et al. 2011. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 17(12):1636-40
129. Pathare GR, Nagy I, Sledz P, Anderson DJ, Zhou H-J, et al. 2014. Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11. PNAS 111(8):2984-89
130. Worden EJ, Padovani C, Martin A. 2014. Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate deubiquitination during proteasomal degradation. Nat. Struct. Mol. Biol. 21:220-27
131. Gallery M, Blank JL, Lin Y, Gutierrez JA, Pulido JC, et al. 2007. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol. Cancer Ther. 6(1):262-68
132. SpataroV, SimmenK, RealiniCA. 2002. The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells. Anticancer Res. 22(6C):3905-9
133. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, et al. 2011. FAS and NF-B signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523-26